{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:53:46Z","timestamp":1789685626257,"version":"4.0.1"},"reference-count":20,"publisher":"Society for Clinical Epidemiology","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Clin Epidemiol","ACE"],"published-print":{"date-parts":[[2026,4,1]]},"DOI":"10.37737\/ace.26007","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T22:07:47Z","timestamp":1763417267000},"page":"54-61","source":"Crossref","is-referenced-by-count":1,"title":["Effect of a financial incentive scheme on promoting prescription of biosimilars: a interrupted time-series analyses"],"prefix":"10.37737","volume":"8","author":[{"given":"Takahito","family":"Morita","sequence":"first","affiliation":[{"name":"Department of Clinical Epidemiology and Health Economics, Graduate School of Medicine, The University of Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Sasabuchi","sequence":"additional","affiliation":[{"name":"Department of Real-world Evidence, Graduate School of Medicine, The University of Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Yasunaga","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Health Economics, Graduate School of Medicine, The University of Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"24670","reference":[{"key":"1","unstructured":"1. Sakamaki H, Ito H, Yuasa A. Future biopharmaceutical market size estimation and effect of biosimilars on managing medical expenditure in Japan. Jpn Pharmacol Ther 2021;49:691\u2013700 (in Japanese)."},{"key":"2","unstructured":"2. Office of Pharmaceutical Industry Research. Comparison of new drug approval status and review periods in Japan, the U.S., and Europe based on approval status of biopharmaceuticals. Available from: https:\/\/www.jpma.or.jp\/opir\/news\/067\/bi62u800000003sb-att\/67_12.pdf, Accessed 2025 Feb 10 (in Japanese)."},{"key":"3","unstructured":"3. Office of Pharmaceutical Industry Research. New drugs approved in Japan and review periods: approval results and trends over time in 2022. Available from: https:\/\/www.jpma.or.jp\/opir\/news\/068\/m7cl5500000004v6-att\/68_13.pdf, Accessed 2025 Feb 10 (in Japanese)."},{"key":"4","unstructured":"4. Office of Pharmaceutical Industry Research. Comparison of the launch status of the world\u2019s top 300 pharmaceutical products in terms of sales in Japan, the U.S. and Europe. Available from: https:\/\/www.jpma.or.jp\/opir\/news\/068\/m7cl5500000004rv-att\/68_12.pdf, Accessed 2025 Feb 10 (in Japanese)."},{"key":"5","unstructured":"5. National Institute of Health Sciences. A list of biosimilars approved in Japan. Available from: https:\/\/www.nihs.go.jp\/dbcb\/TEXT\/bs_j_240103.pdf, Accessed 2025 Feb 10 (in Japanese)."},{"key":"6","unstructured":"6. Ministry of Health, Labour and Welfare. The promotion of biosimilar Available from: https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/kenkou_iryou\/iryou\/kouhatu-iyaku\/index.html, Accessed 2025 Feb 10 (in Japanese)."},{"key":"7","unstructured":"7. Ministry of Health, Labour and Welfare. The overview of medical fee revision in 2020.Available from: https:\/\/www.mhlw.go.jp\/content\/12400000\/000691038.pdf, Accessed 2025 Feb 10 (in Japanese)."},{"key":"8","unstructured":"8. Ministry of Health, Labour and Welfare. Statistics of medical care activities in public health insurance in 2022. Available from: https:\/\/www.e-stat.go.jp\/stat-search\/files?page=1&toukei=00450048&tstat=000001029602, Accessed 2025 Feb 10 (in Japanese)"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Yasunaga H. DeSC database. Ann Clin Epidemiol 2025;7:46\u201349.","DOI":"10.37737\/ace.25006"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Sato S, Sasabuchi Y, Aso S, Okada A, Yasunaga H. Association between subjective physical function and occurrence of new fractures in older adults: a retrospective cohort study. Geriatr Gerontol Int 2024;24:337\u2013343.","DOI":"10.1111\/ggi.14830"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Bottomley C, Ooko M, Gasparrini A, Keogh RH. In praise of prais-winsten: an evaluation of methods used to account for autocorrelation in interrupted time series. Stat Med 2023;42:1277\u20131288.","DOI":"10.1002\/sim.9669"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Zhong X, Xiao LH, Wang DL, Yang SW, Mo LF, He LF, et al. Impact of a quality control circle on the incidence of catheter-associated urinary tract infection: an interrupted time series analysis. Am J Infect Control 2020;48:1184\u20131188.","DOI":"10.1016\/j.ajic.2020.01.006"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Turner SL, Forbes AB, Karahalios A, Taljaard M, McKenzie JE. Evaluation of statistical methods used in the analysis of interrupted time series studies: a simulation study. BMC Med Res Methodol 2021;21:181.","DOI":"10.1186\/s12874-021-01364-0"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Hasebe M, Satoh S, Ito K, Tamura H, Terauchi Y. Endocrinological evaluation of dawn phenomenon in patients with diabetes and comparison of insulin glargine U-100 biosimilar (insulin glargine BS Injection \u2018Lilly\u2019) and glargine U-300 (Lantus XR): a randomized controlled study. Endocr J 2023;70:777\u2013786.","DOI":"10.1507\/endocrj.EJ22-0562"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Herndon K, Braithwaite J, Berry B, Bourget K. Biosimilar perceptions among healthcare professionals and commercial medical benefit policy analysis in the United States. BioDrugs 2021;35:103\u2013112.","DOI":"10.1007\/s40259-020-00463-6"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Bruno F, Carine S, Christophe B, Yves M, Fabienne C, Sonia T, et al. PERFUSE - a real-world study on rheumatology patients\u2019 persistence with adalimumab biosimilar SB5 in France: impacts of patient experience. Open Rheumatol J 2025;19:e18743129328661.","DOI":"10.2174\/0118743129328661241128114825"},{"key":"17","unstructured":"17. Ministry of Health, Labour and Welfare. The report of the verification of medical fee revision in 2020.Available from: https:\/\/www.mhlw.go.jp\/content\/12404000\/000860753.pdf, Accessed 2025 Feb 10 (in Japanese)."},{"key":"18","unstructured":"18. Ministry of Health, Labour and Welfare. The report of the verification of medical fee revision in 2022. Available from: https:\/\/www.mhlw.go.jp\/content\/12404000\/001165883.pdf, Accessed 2025 Feb 10 (in Japanese)."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Kim Y, Kwon HY, Godman B, Moorkens E, Simoens S, Bae SJ. Uptake of biosimilar infliximab in the UK, France, Japan, and Korea: budget savings or market expansion across countries? Front Pharmacol 2020;11:970.","DOI":"10.3389\/fphar.2020.00970"},{"key":"20","unstructured":"20. Ministry of Health, Labour and Welfare. The information about the revision of drug prices in 2020. Available from: https: \/\/www.mhlw.go.jp\/topics\/2020\/04\/dl\/tp20210218\u201301_02.pdf, Accessed 2025 May 18 (in Japanese)."}],"container-title":["Annals of Clinical Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ace\/8\/2\/8_26007\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T04:18:48Z","timestamp":1775276328000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ace\/8\/2\/8_26007\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.37737\/ace.26007","relation":{},"ISSN":["2434-4338"],"issn-type":[{"value":"2434-4338","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"article-number":"26007"}}